Speaker Profile

Ph.D., Sr. Scientific & Clinical Affairs Specialist, Novosanis

Jhana Hendrickx holds a master degree in bio-engineering, specializing in cell and gene biotechnology and applications for human health engineering, and a doctoral degree in biomedical sciences. Jhana joined Novosanis, a medical device company and subsidiary of OraSure Technologies Inc., in 2021. She’s in charge of scientific affairs, managing the Key Opinion Leader network, running Scientific Advisory Boards and engaging with our customers. Also, she is in charge of clinical affairs and runs the in-house clinical trials in infectious diseases and oncology and supports trials executed by lead Principal Investigators globally.


Clinical Dx Showcase:

Novosanis is a wholly owned subsidiary of OraSure Technologies Inc (NASDAQ: OSUR) and an innovative developer and producer of medical devices improving the quality of diagnostic tests for infectious diseases and oncology.

First-Void Urine As A Liquid Biopsy For Disease Monitoring
First-void urine as a non-invasive liquid biopsy for disease monitoring and diagnostics.

 Session Abstract – PMWC 2023 Silicon Valley

Showcase Track S2 - January 25 9.00 A.M.-1.15 P.M.,Showcase Track S2 - January 26 9.00 A.M.-4.45 P.M.,Showcase Track S2 - January 27 9.00 A.M.-2.15 P.M.

The PMWC 2023 Data Applications in Clinical Diagnostics Showcase will provide a 15-minute time slot for selected organizations, including commercial companies, clinical testing labs, and medical research institutions, to present their latest advancements, insights, applications, and technologies to an audience of clinicians, leading investigators, academic institutions, pharma and biotech, investors, and potential clients. We will learn about new technologies and findings that promise expedited, cost-effective, and accurate clinical diagnosis for early disease detection, treatment decisions, and disease prevention.

  • Clinical Dx/Oncology (including Liquid Biopsy)
  • Clinical Dx/Cardio Vascular
  • Clinical Dx/Nerodegenerative